Item 8.01. Other Events. On March 23, 2026, Abbott Laboratories, an Illinois corporation (“Abbott”), completed the acquisition of Exact Sciences Corporation, a Delaware corporation (“Exact Sciences”), pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among Abbott, Exact Sciences and Badger Merger Sub I, Inc., a Delaware corporation and a d…
Filed Mar 23, 2026Accepted Mar 23, 2026, 8:54 AM EDTCIK 1800Accession 0001104659-26-033079
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X, and YouTube.
Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 8.01Item 8.01 - Other Events
Item 8.01. Other Events.
On March 23,
2026, Abbott Laboratories, an Illinois corporation (“Abbott”), completed the acquisition of Exact Sciences Corporation, a
Delaware corporation (“Exact Sciences”), pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the
“Merger Agreement”), by and among Abbott, Exact Sciences and Badger Merger Sub I, Inc., a Delaware corporation and a direct,
wholly owned subsidiary of Abbott (“Merger Sub”). Pursuant to the terms of, and subject to the conditions contained in, the
Merger Agreement, Merger Sub merged with and into Exact, with Exact surviving as a direct, wholly owned subsidiary of Abbott (the “Merger”).
At the effective
time of the Merger (the “Effective Time”), each share of common stock, par value $0.01 per share, of Exact Sciences issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was
automatically converted into the right to receive $105.00 in cash, without interest, less any applicable withholding taxes.
The foregoing
description of the Merger and the Merger Agreement is not complete and is qualified in its entirety by reference to the Merger Agreement,
which is included as Exhibit 2.1 and is incorporated herein by reference.
On March 23,
2026, Abbott issued a press release announcing the closing of the Merger, a copy of which is filed as Exhibit 99.1 and is incorporated
herein by reference.
Filed exhibits (1)
EX-99.1 (by filename) tm268709d2_ex99-1.htm
EX-99.1
2
tm268709d2_ex99-1.htm
EXHIBIT 99.1
Exhibit 99.1
News Release
Abbott completes acquisition of Exact
Sciences
Establishes
Abbott as a leader in fast-growing cancer screening and diagnostics segments
Advances
Abbott’s mission to make healthcare more accessible and give people more control over
their health
ABBOTT PARK, Ill., March 23, 2026 - Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing
cancer screening and diagnostics segments and enabling the company to serve millions of additional people.
“Abbott’s global scale,
track record of operational and commercial excellence and work with healthcare systems around the world will expand access to important
tools for early cancer detection and personalized treatments,” said Robert B. Ford, chairman and chief executive officer, Abbott.
“With the legacy and deep expertise of the Exact Sciences team, we’re ready to transform cancer care.”
Pursuant to the terms of the merger agreement, upon completion of
the acquisition, Exact Sciences became a wholly owned subsidiary of Abbott. As a result of the completion of the acquisition,…